These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26409286)

  • 1. Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done.
    Schito M; Maeurer M; Kim P; Hanna D; Zumla A
    Clin Infect Dis; 2015 Oct; 61Suppl 3(Suppl 3):S95-101. PubMed ID: 26409286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.
    Schito M; Migliori GB; Fletcher HA; McNerney R; Centis R; D'Ambrosio L; Bates M; Kibiki G; Kapata N; Corrah T; Bomanji J; Vilaplana C; Johnson D; Mwaba P; Maeurer M; Zumla A
    Clin Infect Dis; 2015 Oct; 61Suppl 3(Suppl 3):S102-18. PubMed ID: 26409271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
    Wallis RS; Maeurer M; Mwaba P; Chakaya J; Rustomjee R; Migliori GB; Marais B; Schito M; Churchyard G; Swaminathan S; Hoelscher M; Zumla A
    Lancet Infect Dis; 2016 Apr; 16(4):e34-46. PubMed ID: 27036358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.
    Kaufmann SH; Lange C; Rao M; Balaji KN; Lotze M; Schito M; Zumla AI; Maeurer M
    Lancet Respir Med; 2014 Apr; 2(4):301-20. PubMed ID: 24717627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zero deaths from tuberculosis: progress, reality, and hope.
    Zumla A; Kim P; Maeurer M; Schito M
    Lancet Infect Dis; 2013 Apr; 13(4):285-7. PubMed ID: 23531385
    [No Abstract]   [Full Text] [Related]  

  • 6. Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuberculosis.
    Mwaba P; McNerney R; Grobusch MP; O'Grady J; Bates M; Kapata N; Maeurer M; Zumla A
    Trop Med Int Health; 2011 Jul; 16(7):819-27. PubMed ID: 21489070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.
    Zumla A; Chakaya J; Centis R; D'Ambrosio L; Mwaba P; Bates M; Kapata N; Nyirenda T; Chanda D; Mfinanga S; Hoelscher M; Maeurer M; Migliori GB
    Lancet Respir Med; 2015 Mar; 3(3):220-34. PubMed ID: 25773212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical testing of new drugs for tuberculosis: current challenges.
    Lenaerts AJ; Degroote MA; Orme IM
    Trends Microbiol; 2008 Feb; 16(2):48-54. PubMed ID: 18182291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in rapid diagnosis of tuberculosis disease and anti-tuberculous drug resistance.
    Alcaide F; Coll P
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():34-40. PubMed ID: 21420565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates.
    Zumla A; Maeurer M;
    Clin Infect Dis; 2015 Nov; 61(9):1432-8. PubMed ID: 26219693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.
    Tiberi S; du Plessis N; Walzl G; Vjecha MJ; Rao M; Ntoumi F; Mfinanga S; Kapata N; Mwaba P; McHugh TD; Ippolito G; Migliori GB; Maeurer MJ; Zumla A
    Lancet Infect Dis; 2018 Jul; 18(7):e183-e198. PubMed ID: 29580819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing.
    Laurenzo D; Mousa SA
    Acta Trop; 2011 Jul; 119(1):5-10. PubMed ID: 21515239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    Respir Med; 2009 Dec; 103(12):1777-90. PubMed ID: 19660927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advancements in the development of anti-tuberculosis drugs.
    Chetty S; Ramesh M; Singh-Pillay A; Soliman ME
    Bioorg Med Chem Lett; 2017 Feb; 27(3):370-386. PubMed ID: 28017531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.